The associations between polymorphisms in the CD36 gene, fat oxidation and cardiovascular disease risk factors in a young adult Australian population: A pilot study

**Introduction**

CD36 gene variants have been associated with metabolic and cardiovascular disease (CVD) [1–4]. However, a move from association to causality is required to elucidate the roles of specific genes in the pathogenesis of obesity related diseases [5]. The 88 kDa multifunctional membrane glycoprotein encoded by the CD36 gene is expressed in a number of cells [6], but its facilitation of cellular fatty acid (FA) uptake is of interest when we explore associations with chronic disease [7].

At present, there is no data relating to CD36 gene variants in an Australian cohort. Particular emphasis on a young, healthy cohort in this functional genetic study minimizes secondary phenotypic influence from overt pathology commonly present in older cohorts, allowing for identification of early indicators in a hypothesized ‘at-risk’ population.

Our aim was to investigate two CD36 single nucleotide polymorphisms (SNPs) (rs1527479 and rs1984112), previously associated with chronic disease in older populations [2,3], and examine associations with CVD risk factors, as well as whole body fat oxidation (\(\text{Fat}_{\text{ox}}\)) during exercise.

**Methods and procedures**

Twenty-two (15 men/7 women; 18–30 years) physically active non-smokers, who were capable of performing an incremental cycling test to exhaustion volunteered for the study. This study was approved by the University of Sydney Human Research Ethics Committee.

**Phenotyping**

Participants reported to the laboratory on two occasions following a 10-h fast (>1-wk apart). Participants abstained from alcohol, caffeine and strenuous exercise for 24-h prior to each session. Women attended during the early-to-mid follicular phase of their menstrual cycle [8].
Session one involved blood sample collection for DNA extraction, body composition [bio-electrical impedance analysis (BIA)] and maximal oxidative capacity (VO2peak) assessment using an incremental cycling test.

Session two included measurement of resting CVD risk factors, namely resting heart rate (RHR), blood pressure (BP) and rate-pressure product (RPP), and assessment of FatOx during a sub-maximal cycling task. Participants followed a controlled diet normalized to body weight (175 kJ/kg), on the day prior to assessment [9]. Six 6-min sub-maximal stages representing 30–80% VO2peak were used to assess FatOx. Ventilatory gas was collected for the final 2-min of each stage. FatOx was calculated using non-protein respiratory quotient [10].

Genotyping

Genomic DNA was extracted from whole blood. C/T SNP rs1527479 (intron 1B, −3489-bp relative to translation start site) and G/A SNP rs1984112 (5′ flanking exon 1A, −33137-bp relative to translation start site) were genotyped using custom Taqman® real-time polymerase chain reaction (PCR) technology (VIC® and FAM™ labelled-dyes).

Statistical analyses

Data are presented as mean ± SE or median (range). Both SNPs were tested for departure from Hardy–Weinberg equilibrium using chi-square analysis. Sequential one-way ANCOVA models were constructed to determine differences across genotypes at both loci. Dominant allele ANCOVA models were also performed (SNP carriers vs. non-carriers). All ANCOVA models were adjusted for age, sex and VO2peak. Post hoc analysis was conducted using Fisher’s LSD test. p < 0.05 was considered significant. Post hoc analyses were considered for all ANCOVA models where p < 0.1 due to limited sample size. Statistical analyses were performed using SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA), and effect sizes (Cohen’s d) calculated using G*Power 3.1.2 (Kiel, Germany) [11].

Results

Genotype distribution at both SNP loci were in Hardy-Weinberg equilibrium. TT carriers at rs1527479 had significantly lower FatOx at 40% VO2peak than CC carriers (p = 0.036) (Fig. 1). TT participants also tended towards lower FatOx at 30%

Figure 1 Fat oxidation (FatOx) rates were obtained during a six stage submaximal cycling test, corresponding to 30–80% VO2peak. Results are stratified by genotype at SNP rs1527479; CC (circles, n = 6), CT (squares, n = 9) and TT (triangles, n = 7). Results are expressed as mean ± SE, with data at 40% VO2peak log transformed prior to using parametric statistics. All data adjusted for age, sex and VO2peak. * Significance at p < 0.05.

VO2peak (p = 0.088, d = 1.3) during dominant allele analysis (data not shown).

TT carriers had significantly higher RHR compared to CC (p = 0.016) and CT (p = 0.008) carriers (Table 1), as well as C-allele carriers in dominant allele analysis (p = 0.003) (Table 2). RPP was significantly higher in TT carriers compared to CT (p = 0.024) and C-allele (p = 0.029) carriers.

Wild-type GG carriers at rs1984112 showed significantly elevated RHR (p = 0.005). DBP was significantly lower in AA carriers at rs1984112 compared to GA (p = 0.02) and G-allele carriers overall (p = 0.013). No significant difference in FatOx data was present in rs1984112 using either model (data not shown).

No differences were observed in VO2peak or % body fat at either SNP loci using either model.

Discussion

TT carriers at rs1527479 were observed to have lower rates of FatOx at 40% VO2peak. Post hoc analysis of both SNPs using both models identified large effect sizes (d = 0.7–1.4) at lower exercise intensities (30–40% VO2peak), highlighting the potential influence of CD36 in FA mobilization. A rare CD36 deficiency has been associated with increased serum FA concentration and lower ventilatory threshold during exercise, postulated to be a result of increased glucose oxidation [12].

Analysis of CVD risk factors in our cohort identified interesting associations, in particular RHR. TT
Table 1 Clinical characteristics of all participants according to genotype at both SNP loci.

<table>
<thead>
<tr>
<th></th>
<th>rs1527479 variants</th>
<th>rs1984112 variants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC (n = 6)</td>
<td>CT (n = 9)</td>
</tr>
<tr>
<td>Age (year)</td>
<td>23.4 ± 1.0</td>
<td>22.1 ± 0.7</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>69.9 ± 5.7</td>
<td>74.5 ± 4.8</td>
</tr>
<tr>
<td>BF (%)</td>
<td>19.1 ± 1.3</td>
<td>22.6 ± 2.4</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>127 ± 2*</td>
<td>115 ± 2*</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>77 ± 3</td>
<td>75 ± 3</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>93 ± 2</td>
<td>89 ± 3</td>
</tr>
<tr>
<td>RHR (bpm)</td>
<td>55 ± 3*</td>
<td>56 ± 2*</td>
</tr>
<tr>
<td>RPP (mmHg.bpm)</td>
<td>6944 ± 422</td>
<td>6431 ± 318*</td>
</tr>
<tr>
<td>VO2peak (L.min⁻¹)</td>
<td>3.3 ± 0.4</td>
<td>3.0 ± 0.4</td>
</tr>
<tr>
<td>POpeak (W)</td>
<td>296 ± 26</td>
<td>261 ± 28</td>
</tr>
</tbody>
</table>

Values are presented as means ± standard error. Non-normally distributed values are represented as median (range). All data adjusted for age, sex and VO2peak. BF, body fat; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RHR, resting heart rate; RPP, rate-pressure product; VO2peak, maximal oxidative capacity; POpeak, peak power output.

* Significance at p < 0.05.
† Significance at p < 0.01.
‡ Significance at p < 0.005.

Table 2 Dominant allele model analyses of clinical characteristics at both SNP loci.

<table>
<thead>
<tr>
<th></th>
<th>rs1527479 variants</th>
<th>rs1984112 variants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C-Allele (n = 15)</td>
<td>TT (n = 7)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>22.1 ± 0.8</td>
<td>21.9 ± 0.7</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>72.7 ± 3.6</td>
<td>70.6 ± 5.2</td>
</tr>
<tr>
<td>BF (%)</td>
<td>21.2 ± 1.6</td>
<td>18.2 ± 2.4</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>120 ± 2</td>
<td>118 ± 4</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76 ± 2</td>
<td>81 ± 3</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>91 ± 2</td>
<td>94 ± 3</td>
</tr>
<tr>
<td>RHR (bpm)</td>
<td>56 ± 2*</td>
<td>69 ± 4*</td>
</tr>
<tr>
<td>RPP (mmHg.bpm)</td>
<td>6340 (3256*)</td>
<td>7000 (4746*)</td>
</tr>
<tr>
<td>VO2peak (L.min⁻¹)</td>
<td>3.1 ± 0.3</td>
<td>3.0 ± 0.3</td>
</tr>
<tr>
<td>POpeak (W)</td>
<td>275 ± 20</td>
<td>286 ± 15</td>
</tr>
</tbody>
</table>

Normally distributed values presented as means ± SE. Non-normally distributed values are represented as median (range). All data adjusted for age, sex and VO2peak. BF, body fat; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RHR, resting heart rate; RPP, rate-pressure product; VO2peak, maximal oxidative capacity; POpeak, peak power output.

* Significance at p < 0.05.
† Significance at p < 0.01.
‡ Significance at p < 0.005.

carriers at rs1527479, and GG carriers at rs1984112, had significantly elevated RHR values, independent of fitness related variables. Although non-clinical, these participants could be at an increased risk of future CVD due to the linear association between RHR above 60 beats per minute and CVD [13,14].

Additionally, the association between both SNP loci and BP in our young cohort is of particular interest. A model of CD36 deficiency showed that these participants had significantly higher BP [15]. No other data has identified an association between CD36 genotype and altered BP directly.

In summary, CD36 genotype was associated with Fatox, RHR, RPP and BP, possibly affecting future chronic disease risk in healthy individuals. Validation of these findings in larger cohort studies is warranted.

References

Research Letter


Avindra F. Jayewardene*  
Tom Gwinn  
Exercise Health and Performance Faculty Research Group, Faculty of Health Sciences, University of Sydney, Lidcombe, NSW, Australia

Dale P. Hancock  
School of Molecular Biosciences, Faculty of Science, University of Sydney, Camperdown, NSW, Australia

Yorgi Mavros  
Kieron B. Rooney  
Exercise Health and Performance Faculty Research Group, Faculty of Health Sciences, University of Sydney, Lidcombe, NSW, Australia

* Corresponding author at: C42 — Cumberland Campus, Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW 2141, Australia. Tel.: +61 2 9351 9403; fax: +61 2 9351 9204.

E-mail address: ajay5611@uni.sydney.edu.au  
(A.F. Jayewardene)

23 August 2014